CONCERTO trial in patients with relapsing- remitting MS has not reported results. Ozanimod is an orally-administered, selective S1P product. It is being studied in patients with relapsing-remitting MS. While preliminary data suggests that ozanimod may have a preferred safety profile to fingolimod (Gilenya), the currently approved S1P agent, and possibly some of the other pipeline S1P products, Dr.Throwercautions against making any conclusions until more data are available. In one trial, the mean number of gadolinium (Gd)-enhancing lesions and new/enlarging T2 lesions were significantly decreased with ozanimod compared with placebo. The most commonly reported adverse events in this trial included common cold symptoms, headache, and urinary-tract infections. Electrocardiograms and 24-hour Holter monitoring showed no increased incidence of atrioventricular block or sinus pause with ozanimod. The phase III SUNBEAM trial has not reported results. Ponesimod is also an orally-administered, selective S1P that is being studied in patients with relapsing-remitting MS. In a phase II trial, the mean cumulative number of new T1 Gd-enhancing lesions was significantly reduced with ponesimod compared with placebo. Additionally, mean annualized relapse rates were lower with ponesimod 40mg compared with placebo. The most commonly reported adverse events with ponesimod included anxiety, dizziness, breathing difficulty, increased liver enzymes, influenza, insomnia, and peripheral edema. Phase III OPTIMUM trial has not reported results. Siponimod is another orally-administered S1P. It is being studied in patients with both relapsing-remitting and secondaryprogressive MS. In a phase II trial in relapsing-remitting MS, there were reductions in unique active lesionsatthreemonthscomparedwithplacebo. Common adverse events included headache, abnormal heartbeat, dizziness, and infections of the nose and throat. In a phase III trial in patients with secondary-progressive MS, siponimod significantly reduced confirmed disability progression vs. placebo. Common adverse events included headache, common cold symptoms, urinary tract infections, falls, and hypertension. Ofatumumabisasubcutaneously-administered DMT being investigated in patients with relapsing-remitting MS. It works by depleting 58 msfocusmagazine.org Medicine & Research Treatment Administered Types of MS in Trial Laquinimod Oral RRMS, SPMS Ozanimod Oral RRMS Ponesimod Oral RRMS Siponimod Oral RRMS, SPMS Ofatumumab Injection RRMS Masitinib Oral PMS, PPMS